新型β-内酰胺/β-内酰胺酶抑制剂复方制剂和头孢地尔在 …… 中小碳青霉烯酶对其敏感性的影响
Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in .
机构信息
Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
Department of Food Hygiene and Control, Faculty of Veterinary Medicine, South Valley University, Qena, Egypt.
出版信息
Antimicrob Agents Chemother. 2023 May 17;67(5):e0007823. doi: 10.1128/aac.00078-23. Epub 2023 Apr 11.
Abstract
The activity of imipenem-relebactam, meropenem-vaborbactam, ceftazidime-avibactam, and cefiderocol was evaluated against both clinical and isogenic enterobacterial isolates producing carbapenemases of the SME, NmcA, FRI, and IMI types. Ceftazidime-avibactam and meropenem-vaborbactam showed the highest activity against all tested isolates; imipenem-relebactam showed only moderate activity. All isolates remained susceptible to cefiderocol. Furthermore, avibactam and vaborbactam have greater inhibitory activity than relebactam against the tested carbapenemases. Overall, ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol were the most effective therapeutic options for treating infections caused by the tested minor carbapenemase producers.
摘要
研究评估了亚胺培南-雷巴坦、美罗培南-沃巴坦、头孢他啶-阿维巴坦和头孢地尔在针对产 SME、NmcA、FRI 和 IMI 型碳青霉烯酶的临床和同源肠杆菌分离株中的活性。头孢他啶-阿维巴坦和美罗培南-沃巴坦对所有测试分离株显示出最高的活性；亚胺培南-雷巴坦显示出中等活性。所有分离株对头孢地尔仍保持敏感。此外，阿维巴坦和沃巴坦对测试的碳青霉烯酶的抑制活性大于雷巴坦。总体而言，头孢他啶-阿维巴坦、美罗培南-沃巴坦和头孢地尔是治疗测试的低水平碳青霉烯酶产生菌引起的感染的最有效治疗选择。
相似文献
1
Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in .新型β-内酰胺/β-内酰胺酶抑制剂复方制剂和头孢地尔在 …… 中小碳青霉烯酶对其敏感性的影响
Antimicrob Agents Chemother. 2023 May 17;67(5):e0007823. doi: 10.1128/aac.00078-23. Epub 2023 Apr 11.
2
Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.头孢地尔肟与新型β-内酰胺/β-内酰胺酶抑制剂组合对高、低通透性条件下表达单种和双种β-内酰胺酶的同源大肠埃希菌的活性。
Int J Antimicrob Agents. 2024 May;63(5):107150. doi: 10.1016/j.ijantimicag.2024.107150. Epub 2024 Mar 19.
3
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.头孢他啶/阿维巴坦、美罗培南/沃巴坦和亚胺培南/雷利巴坦对美国医院碳青霉烯酶阴性碳青霉烯类耐药肠杆菌科分离株的活性。
Int J Antimicrob Agents. 2021 Nov;58(5):106439. doi: 10.1016/j.ijantimicag.2021.106439. Epub 2021 Sep 20.
4
Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.头孢他啶-阿维巴坦对产 KPC-2 的肠杆菌科的抗菌活性：雷巴他定和沃巴他定联合用药及剂量递增滴定研究。
Microbiol Spectr. 2024 Jun 4;12(6):e0034424. doi: 10.1128/spectrum.00344-24. Epub 2024 Apr 30.
5
Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.新型β-内酰胺/β-内酰胺酶抑制剂联合制剂对产丝氨酸碳青霉烯酶的碳青霉烯类耐药铜绿假单胞菌的活性。
J Antimicrob Chemother. 2023 Dec 1;78(12):2795-2800. doi: 10.1093/jac/dkad225.
6
Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).头孢地尔罗与新型β-内酰胺类-β-内酰胺酶抑制剂联合制剂对产金属β-内酰胺酶革兰氏阴性杆菌的活性：一项为期两年（2019-2020 年）研究的见解。
J Chemother. 2023 May;35(3):198-204. doi: 10.1080/1120009X.2022.2090615. Epub 2022 Jun 22.
7
Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?对头孢地尔敏感性降低/耐药的多重耐药革兰氏阴性临床分离株：目前和未来最佳的治疗替代方案有哪些？
Eur J Clin Microbiol Infect Dis. 2024 Feb;43(2):339-354. doi: 10.1007/s10096-023-04732-4. Epub 2023 Dec 14.
8
Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).在欧洲、拉丁美洲和亚太地区（2020-2022 年）收集的对最近批准的β-内酰胺酶抑制剂组合耐药的肠杆菌科的阿维巴坦-阿唑巴坦活性。
Int J Antimicrob Agents. 2024 Apr;63(4):107113. doi: 10.1016/j.ijantimicag.2024.107113. Epub 2024 Feb 12.
9
Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil.巴西住院患者血流感染碳青霉烯类耐药肺炎克雷伯菌的新型β-内酰胺/β-内酰胺酶抑制剂组合的药敏评估。
J Glob Antimicrob Resist. 2024 Sep;38:247-251. doi: 10.1016/j.jgar.2024.06.007. Epub 2024 Jun 25.
10
In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex.头孢他啶/阿维巴坦、头孢地尔、美罗培南/沃巴坦和亚胺培南/雷利巴坦对嗜麦芽窄食单胞菌复合群临床分离株的体外活性。
PLoS One. 2024 Apr 18;19(4):e0298577. doi: 10.1371/journal.pone.0298577. eCollection 2024.
引用本文的文献
1
Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.评估新型头孢地尔肟的活性和耐药机制，以及β-内酰胺类药物与新型β-内酰胺酶抑制剂阿维巴坦、替加环素、唑巴坦、奈拉滨、西罗莫司他和 ANT3310 联合使用对新兴产双重碳青霉烯酶肠杆菌科的作用机制。
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0092424. doi: 10.1128/aac.00924-24. Epub 2024 Oct 9.
2
Improved Blue Carba test and Carba NP test for detection and classification of major Class A and B carbapenemases, including dual producers, among Gram-negative bacilli.改良的 Blue Carba 试验和 Carba NP 试验用于检测和分类革兰氏阴性杆菌中的主要 A 类和 B 类碳青霉烯酶，包括双重产酶者。
J Clin Microbiol. 2024 Jul 16;62(7):e0125523. doi: 10.1128/jcm.01255-23. Epub 2024 Jun 21.
3
Opportunities and challenges of microbial siderophores in the medical field.微生物铁载体在医学领域的机遇与挑战
Appl Microbiol Biotechnol. 2023 Nov;107(22):6751-6759. doi: 10.1007/s00253-023-12742-7. Epub 2023 Sep 27.
4
An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms.头孢地尔的治疗潜力及潜在耐药机制概述
Life (Basel). 2023 Jun 21;13(7):1427. doi: 10.3390/life13071427.
本文引用的文献
1
Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.获得性广谱β-内酰胺酶对大肠埃希菌和铜绿假单胞菌对头孢地尔罗和新开发的β-内酰胺/β-内酰胺酶抑制剂组合的敏感性的影响。
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0003922. doi: 10.1128/aac.00039-22. Epub 2022 Mar 22.
2
Emergence of rare carbapenemases (FRI, GES-5, IMI, SFC and SFH-1) in Enterobacterales isolated from surface waters in Japan.在从日本地表水中分离出的肠杆菌科细菌中出现罕见碳青霉烯酶（FRI、GES-5、IMI、SFC和SFH-1）
J Antimicrob Chemother. 2022 Apr 27;77(5):1237-1246. doi: 10.1093/jac/dkac029.
3
Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants.产 KPC 变体的临床分离株对头孢他啶-阿维巴坦和头孢地尔的共同耐药性。
Eur J Clin Microbiol Infect Dis. 2022 Apr;41(4):677-680. doi: 10.1007/s10096-021-04397-x. Epub 2022 Jan 28.
4
Characterization of FRI carbapenemase-producing Enterobacter spp. isolated from a hospital and the environment in Osaka, Japan.从日本大阪一家医院及环境中分离出的产FRI碳青霉烯酶肠杆菌属的特性分析
J Antimicrob Chemother. 2021 Oct 11;76(11):3061-3062. doi: 10.1093/jac/dkab284.
5
Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.鲍曼不动杆菌中 PER 型和 NDM 型β-内酰胺酶对头孢地尔罗耐药性的贡献。
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0087721. doi: 10.1128/AAC.00877-21. Epub 2021 Jul 12.
6
Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".对新型β-内酰胺-β-内酰胺酶抑制剂组合的耐药性：“进步的代价”。
Infect Dis Clin North Am. 2020 Dec;34(4):773-819. doi: 10.1016/j.idc.2020.05.001. Epub 2020 Sep 30.
7
Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.亚胺培南-雷巴他定和美罗培南-沃诺拉赞对产 SME 碳青霉烯酶耐药黏质沙雷氏菌的活性。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02255-19.
8
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin.头孢地尔罗：一种新型铁载体头孢菌素的发现、化学结构和体内特征。
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S538-S543. doi: 10.1093/cid/ciz826.
9
Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria.革兰氏阴性菌碳青霉烯类耐药的流行病学和诊断学。
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S521-S528. doi: 10.1093/cid/ciz824.
10
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.碳青霉烯类耐药革兰氏阴性菌感染的治疗选择。
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S565-S575. doi: 10.1093/cid/ciz830.
Zotero 插件